Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 4/20 | 0.55 |
| ▸ | NFKB2 | Q00653 | 4/20 | 0.55 |
| ▸ | RELA | Q04206 | 4/20 | 0.55 |
| ▸ | BTK | Q06187 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | KDM1A | O60341 | 2/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2630498 | 1.00 | NFKB1 (0.55) | NFKB1NFKB2RELABTKMAPT | |
| SCHEMBL22241778 | 1.00 | NFKB1 (0.55) | NFKB1NFKB2RELABTKMAPT | |
| Bicarbonate SCHEMBL6014904 | 0.97 | NFKB1 (0.53) | NFKB1NFKB2RELABTKMAPT | |
| SCHEMBL19258039 | 0.90 | NFKB1 (0.53) | NFKB1NFKB2RELABTKCTSK | |
| Methanesulfonic Acid Methyl Ester SCHEMBL3901628 | 0.90 | NFKB1 (0.47) | NFKB1NFKB2RELABTKMAPT | |
| SCHEMBL18024827 | 0.87 | NFKB1 (0.50) | NFKB1NFKB2RELABTKCTSK | |
| SCHEMBL10538036 | 0.82 | MAPT (0.57) | NFKB1NFKB2RELAMAPTEPHX2 | |
| SCHEMBL1928948 | 0.80 | NFKB1 (0.56) | NFKB1NFKB2RELABTKCTSK | |
| SCHEMBL17991584 | 0.79 | NFKB1 (0.44) | NFKB1NFKB2RELABTKMAPT | |
| SCHEMBL17992573 | 0.79 | MAPT (0.48) | NFKB1NFKB2RELABTKMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8524943-B2 | Production of trans-4-aminocyclopent-2-ene-1-carboxylic acid derivatives | DR. REDDY'S LABORATORIES, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-20120101297-A1 | PRODUCTION OF TRANS-4-AMINOCYCLOPENT-2-ENE-1-CARBOXYLIC ACID DERIVATIVES | DR. REDDY'S LABORATORIES, INC. (US) | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101297-A1 | PRODUCTION OF TRANS-4-AMINOCYCLOPENT-2-ENE-1-CARBOXYLIC ACID DERIVATIVES | COASY, BCAT1, ALDH7A1 | NFKB1 1427/4885NFKB2 2293/4885RELA 2244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.